Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07119970
Recruiting Not applicable

Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

NCT07119970 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Bordeaux
Phase
Not applicable
Started
2025-12-09
Last updated
2026-01-13

Condition(s) studied

Myeloproliferative NeoplasmMyeloproliferative Disorders

Investigational drug(s) / intervention(s)

Additional blood sampling →

Additional blood sampling: At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis

Study summary

Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF) * JAK2V617F mutation with an allelic burden greater than 1% * High risk of thrombosis (age over 60 years or prior thrombotic event) * Diagnosis of MPN within the last 12 months * Enrollment in the AVAJAK clinical trial and the FIMBANK biobank * Affiliation with social security * Signed informed consent Exclusion Criteria: * Severe hepatic or renal insufficiency (Creatinine clearance \<30ml/min) * Patients under legal protection (guardianship or curatorship) * Patients under heparin treatment at inclusion

Primary outcome measure(s)

Trial sites (15)

FacilityCityRegionStatus
CHU d'Angers, Service des maladies du Sang Angers France Not Yet Recruiting
CH de la Côte Basque, Service Hématologie Bayonne France Not Yet Recruiting
CHU de Bordeaux, Service Hématologie Biologique Bordeaux France Not Yet Recruiting
CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire Bordeaux France Not Yet Recruiting
CHU de Brest, Service Hématologie et Hémostase Clinique Brest France Not Yet Recruiting
APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire Créteil France Not Yet Recruiting
CHD de Vendée, Service Onco-hématologie La Roche-sur-Yon France Not Yet Recruiting
APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire Le Kremlin-Bicêtre France Not Yet Recruiting
CH de Libourne, Service Hématologie Libourne France Recruiting
CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire Limoges France Not Yet Recruiting
CH des Pays de Morlaix, Service Onco-Hématologie Morlaix France Not Yet Recruiting
CHU de Nantes, Service Hématologie Clinique Nantes France Not Yet Recruiting
Hôpital Privé du Confluent, Service Hématologie Nantes France Not Yet Recruiting
APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques Paris France Not Yet Recruiting
CH de Roubaix, Service Hématologie Roubaix France Not Yet Recruiting

More University Hospital, Bordeaux trials in France

Diagnosis of Respiratory Disorders by the Numerical Modeling. Recruiting
Neuro-cardiac Rehabilitation in Youth With Congenital Heart Disease (QUALINEUROREHAB) Recruiting
Evaluation of the Evolution of Patient Care Within the Spinal Pathology Department Recruiting
The Role of Cxcr4Hi neutrOPhils in InflueNza Recruiting
Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction Starting soon

Other trials for the same condition

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Recruiting
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP) Recruiting
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions Active, not recruiting
Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07119970 on ClinicalTrials.gov ↗ ← All trials in France